Avraham Pharmaceuticals is a clinical-stage company focused on developing small molecule therapeutics for the treatment of neurodegenerative disorders.
Avrahams lead product candidate, Ladostigil, was exclusively in-licensed from the Hebrew University and Technion Research and Development Foundation Ltd. and company was founded by the inventors of Ladostigil; Prof Marta Weinstock-Rosin, Prof. Moussa B.H. Youdim and Prof. Michael Chorev.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/avraham-pharmaceuticals” connections=”true” suffix=””]
In Feb 2016, Avraham closed an investment round of approx. $4.0 Mn and has raised $18 Mn since formation. Key investors includes Yissum Research Development Company, Pontifax, Clal Biotechnology Industries, Integra Holdings, Yissums biotech holdings company, TRDF and others.
Recover your password.
A password will be e-mailed to you.